Future studies are warranted to increase the level of evidence of use of NOACs, particularly in patients with TAVI and valvular surgery, and to determine whether they could be used in the future in the only two remaining contraindications.
Introduction
Atrial fibrillation (AF) is the most common arrhythmia in clinical practice, with currently in Europe approximately 10 million patients with AF and 100,000-200,000 with new-onset AF. 1 This arrhythmia has a high morbidity and mortality risk, mainly due to the elevated risk of ischemic stroke. The CHA 2 DS 2 VASc score is a validate tool to estimate the annual risk of stroke or systemic embolism, ranging from less than 1% to approximately 20% in the absence of oral anticoagulants. 2 Historically, vitamin-K antagonists (VKA) were the gold-standard treatment for the prevention of systemic embolism. However, this therapy has many downsides, like the interactions with food and other drugs, a narrow therapeutic window, the need for frequent coagulation monitoring and dosage adjustment, or its' particular pharmacokinetics (delayed onset and offset of anticoagulant effect) somehow complicating the management of patients.
Recently, non-VKA Oral Anticoagulants (NOAC) have been introduced. This therapeutic class facilitates the management of oral anticoagulation since the four currently available molecules do not have most of the downsides described above. Though, its use is contraindicated in patients with severe renal impairment and with so-called "valvular AF".
The definition of valvular and non-valvular AF (NVAF) are unclear, varying from one to the other NOAC study, [3] [4] [5] [6] and even between North-American and European guidelines, 7, 8 which is a source of ambiguity in clinicians' minds. A clarification of the term NVAF is needed in order to not deny NOACs to patients based on the wrong perception that they may have NVAF.
In the present comprehensive review, we aimed at clarifying this point, by analyzing results of the main randomized trials in the area and recommendations in current guidelines and by describing the safety and efficacy of NOACs in patients with valvular abnormalities, based on the results of published studies.
The magnitude of the problem
A large proportion of the patients with AF have signs of valvular involvement. Among those included in the EURObservational Research Programme Atrial Fibrillation, a prospective survey in european countries, 63.5% had a valvular disease. 9 The presence of such anomalies increase the risk of AF by 1.8 and 3.4 in men and women, respectively. 10 On the other hand, animal studies have shown that AF, through atrial dilatation, results in a progressive mitral regurgitation, already present at the transition stage between paroxysmal and persistent AF, which becomes significant after one year of long-standing persistent AF. 11 Thus, the M A N U S C R I P T
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4 relationship between both anomalies is frequent and often unclear, particularly in the presence of atrial dilatation.
From NOAC trials to current guidelines
Factor IIa (dabigatran) and factor Xa (rivaroxaban, apixaban, and edoxaban) inhibitors have demonstrated their non-inferiority or superiority compared to VKA to reduce the risk of stroke and systemic thrombo-embolism. [3] [4] [5] [6] In the meta-analysis published in 2014 by Ruff et al 12 compelling the 4 major trials on stroke prevention for AF published so far, a significant reduction of 19% of this endpoint was observed. Importantly, major bleedings were significantly reduced by 14%. In these seminal trials, patients with contra-indications to NOACs were excluded, including those with chronic kidney disease or in case of treatment interactions. One of the major exclusion criteria was the presence of a "valvular" AF, but the definition varied widely between the pivotal trials. As shown in Table 1 , the inclusion criteria of the RE-LY, 4 the ROCKET-AF, 6 the ARISTOTLE, 3 and the ENGAGE-AF TIMI 48 5 trials
were substantially dissimilar. The most restrictive study was the RE-LY trial, 4 since a "history of heart valve disorder (i.e., prosthetic heart valve or hemodynamically relevant valve disease)" was an exclusion criterion. 
Valvular heart diseases, AF and thrombo-embolic risk

Mitral stenosis
Mitral stenosis has historically been considered a distinct disease in the area of AF. Indeed, it results in a low atrial flow, significantly increasing the risk of atrial thrombi, which, besides, are often located in various regions of the atria but the left atrial appendage (91% in NVAF and 57% in AF associated with mitral stenosis). 14 Since the thrombo-embolic risk is increased, and the efficacy of new anticoagulants uncertain, such patients were excluded from randomized controlled trials about NOACs, and to date, there are no data regarding the efficacy and safety of these molecules in patients with mitral stenosis. Whether pathophysiology of thrombi genesis in these patients is substantially different to contraindicate NOAC prescription is unknown and would probably require further studies.
Other valvular diseases
The other valvular diseases (mitral or tricuspid regurgitations, aortic stenosis) were not considered to increase per-se the risk of thrombo-embolic event. However, Philippart et al recently demonstrated that patients with left-sided valvular disease had a 1.39-fold increase risk of stroke/thrombo-embolic events, probably explained by a higher CHA 2 DS 2 -VASc score and significantly more comorbidities in these patients, compared to those with no valvular diseases. 15 Indeed, older age and higher CHA 2 DS 2 -VASc scores were the only independent predictors of ischemic events, but not the presence of a valvular disease.
Many studies have shown that mitral regurgitation might reduce the risk of stroke since atrial flow is increased and atrium and left atrial appendage are "washed" by the regurgitant flow. origin. The severity of those valvular diseases was not reported. 18 To note, 5.3% had prior cardiac valvular surgeries. Baseline characteristics of patients with or without valvular involvement significantly differed, since the former were older and had more comorbidities like congestive heart failure, prior myocardial infarction, chronic obstructive pulmonary disease or smoking. Although rivaroxaban had a similar efficacy in patients with or without valvular disease, a significant lower bleeding rate was observed in the latter group, probably explained by the differences in terms of baseline characteristics. The interaction of valvular disease in patients randomized to rivaroxaban and warfarin was not significant in intention-totreat in terms of efficacy outcomes. However, a significant higher bleeding rate was observed in patients with valvular involvement randomized to rivaroxaban compared to warfarin.
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A similar analysis was performed among patients included in the ARISTOTLE trial comparing efficacy and safety outcomes in patients randomized to apixaban or warfarin. 19 Among the 18 201 patients included, 4808 had valvular heart diseases (26.4%), including mitral, tricuspid and aortic regurgitations, or aortic stenosis, with various grades of severity (from mild to severe). To note, a total of 465 patients with mild mitral stenosis were included, as were 251 patients with prior valve surgeries (see below for details). As previously described in the subanalysis of the ROCKET-AF trial, patients with valvular heart diseases were older and had more comorbidities; CHADS2 score was also significantly higher in this group. Patients with valvular heart disease had higher rates of stroke or systemic embolism (3.2% versus 2.4%; HR, 1.34; 95% CI, 1.10-1.62; p=0.003) and bleeding (4.6% versus 4.3%; HR, 1.11; 95% CI, 0.95-1.29; p=0.21) compared to patients without valvular heart diseases.
However, no differential effect of apixaban over warfarin in patients with and without valvular diseases in reducing stroke and systemic embolism was observed. Similarly, bleeding and mortality were similar among patients randomized to apixaban or warfarin, whether valvular involvement was present or not. 
Mechanical valves
Patients with mechanical valves are at a high risk of thrombo-embolic complications and require permanent anticoagulation after valve implantation. Warfarin has been shown to decrease this risk to an annual rate of 0.7-1%. 21, 22 Thrombi may form directly in the surface of the valve or in the left atrial appendage as a consequence of the low-flow induced by the presence of the valve. During the post-operative time or later during follow-up, AF may appear, further increasing thrombo-embolic risk. The phase-2 RE-ALIGN study was designed to test the safety and efficacy profile of dabigatran in patients with aortic and/or mitral mechanical prosthesis. 23 Drug doses varied from 150 mg x 2 to 300 mg x 2 depending on kidney function and blood concentrations of the molecule. Two populations of patients were studied, i.e. those with early (< 7 days) or late (> 3 months) initiation of dabigatran after the surgery. The trial was terminated prematurely since the use of dabigatran in patients with mechanical prosthesis was associated with an increased risk of thromboembolic and major bleeding complications (5% vs. 0%, and 4% vs 2%, respectively) compared to warfarin. Most thrombo-embolic events occurred in patients from the early-initiation group, while bleeding events occurred similarly in both groups. However, major bleeding occurred only in patients for whom dabigatran was initiated early after the valve implantation, all being pericardial bleeding. Thus, authors conclude that dabigatran is not a safe alternative for patients requiring
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8 anticoagulation after the implantation of a mechanical heart valve, and VKAs remain the gold-standard treatment in such patients.
Bioprosthesis
The antithrombic strategy after bioprosthesis valve implantation is currently controversial, but most of the times, aspirin may be a safe option in such patients in sinus rhythm. [24] [25] [26] [27] Whenever AF occurs, an oral anticoagulation has to be prescribed. 26 As recently demonstrated, the presence of a bioprosthesis is associated with a non-significant increase in stroke/thromboembolic events but is not independently associated with their occurrence. 28 Whether pathophysiology of thrombi formation is sufficiently different in these patients to contraindicate NOAC prescription is unknown.
The only dedicated trial was the DAWA study (Dabigatran versus warfarin after mitral and/or aortic bioprosthesis replacement and atrial fibrillation postoperatively) was designed to compare dabigatran (at a dose of 110 mg x 2) with warfarin in patients with bioprostheses, 29 but results cannot be interpreted due to the very limited number of patients enrolled.
30
To date, the only data available on the efficacy and safety profiles of NOACs in patients with bioprosthesis come from subgroup analyses. The ARISTOTLE trial brings us some insights about this specific group of patients, with data recently presented at the 2015 AHA meeting. 
Trans-aortic valve implantation
Trans-aortic valve implantation (TAVI) has emerged as an alternative to surgical aortic valve replacement for patients with aortic stenosis. Antithrombic management after implantation remains empiric, often based on a dual antiplatelet therapy, associating aspirin and clopidogrel for 3 to 6 months, followed by long-term aspirin or a thienopyridine alone. [25] [26] [27] The optimal management of TAVI recipients experiencing AF is currently unknown. The
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9 ESC and the European Association for CardioThoracic Surgery recommend a combination of VKA and aspirin or thienopyridine, weighed against increased risk of bleeding. 26 Similarly to what was stated for bioprosthetic valves, whether pathophysiology of thrombi formation is sufficiently different in TAVI patients to contraindicate them to NOACs would require further studies, and to the best of our knowledge, there are no data published so far in the literature in this topic.
Moving towards new recommendations?
In 2015, the European Heart Rhythm Association (EHRA) published a practical guide on the use of NOACs in patients with AF. 32 In this position paper, authors state that NVAF refers to "AF that occurs in the absence of mechanical prosthetic heart valves and in the absence of moderate-to-severe mitral stenosis", and add that patients with biological valves or valve repair are in a "grey area" and may be suitable for NOAC prescription. Indeed, it is stated that patients with bioprosthetic heart valves and mitral valve repair are suitable for NOAC therapy Lifelong oral anticoagulation with VKAs is mandatory for patients with mechanical heart valves to prevent thromboembolic complications although lability of INRs is a major drawback in this situation, requiring strict coagulation monitoring and drug-adjustments.
Initial promising results of in-vitro and animal studies showing the efficacy of dabigatran in preventing valve thrombosis raised hope about use of NOACs in patients with mechanical prosthetic heart valves, 33, 34 unfortunately deceived by the results of the RE-ALIGN trial. 23 In-vitro coagulation studies later demonstrated that mechanical heart valves induce a local generation of thrombin via the intrinsic pathway in concentrations that overwhelm the inhibitory effect of dabigatran at clinical doses, 35 probably explaining the negative results of the trial. Whether a similar effect occurs with factor Xa inhibitors would require further studies. Preliminary in-vitro 36 and animal 37 studies demonstrated that high-dosed rivaroxaban might be effective in preventing thromboembolic events after mechanical heart valve replacement. However, in the light of the results of the RE-ALIGN trial, 23 further studies would be needed to provide additional data to support clinical trials evaluating factor Xa inhibitors as an alternative to warfarin in patients with prosthetic heart valves.
Patients with moderate-to-severe mitral stenosis (usually of rheumatic origin) have not been included in NOAC trials on the basis of a potential higher risk and different pathophysiologic mechanism of thrombi formation. The prevalence of rheumatic heart disease, the most common cause of mitral stenosis, is widely variable, remaining a major problem in developing areas of the world. Irrespective to atrial rhythm, thrombo-embolic strokes are frequent, estimated to reach around 4 million events per year. Oral anticoagulation using
VKAs is recommended in patients with mitral stenosis and AF, and may be proposed to patients with mitral stenosis in the absence of AF. [24] [25] [26] [27] However, times in therapeutic range, already suboptimal in developed countries, are even worst in developing parts of the world with high incidence of rheumatic fever. 38 Alternative therapeutic strategies, such as aspirin, are sometimes offered to such patients, despite the well-known inferiority to VKAs. 2 Based on these assumptions, De Caterina and Camm recently wrote "the concept for a trial"
comparing NOACs to the standards of care for thromboembolic prophylaxis (antiplatelet agents or VKA) in patients with mitral stenosis. 39 They claim that a randomized, open-label, superiority trial should be conducted in specific countries with a high prevalence of mitral stenosis using a NOAC available for once daily use (rivaroxaban or edoxaban) to facilitate patients' compliance, at the same dosage used in pivotal trials in AF. The overall sample size would vary depending on the expected stroke rate, the study duration and the expected hazard ratio of stroke reduction, from around 600 to 7000. Such study appears to be feasible, at least by academic centers, if not by pharmaceutical companies, and is warranted to improve the suboptimal current standard antithrombotic treatment of patients with mitral stenosis.
Lastly, it may be now time to stop using the confusing term "non-valvular" to define a type of AF. As stated by De Caterina and Camm, a novel terminology should be used in order to clarify this confusion situation. 40 Authors proposed the term "MARM-AF", acronym standing for "Mechanical And Rheumatic Mitral-AF", since it clearly describes the currently real contraindications to NOACs. The future will tell us whether this term will be life-standing and used by futures researchers.
Conclusion
The term "NVAF" and the inclusion and exclusion criteria in NOACs pivotal trials have created some confusion in physicians' minds about patients who are eligible or not to this therapy. Evidences are progressively coming and showing that NOACs can be safely used in patients with native valvular diseases, regardless of their severity, and probably in bioprosthetic heart valve recipients. The only contraindications remain the presence of a mechanical heart valve and moderate-to-severe mitral stenosis. Future studies are warranted to increase the level of evidence of the safety and efficacy of NOACs in specific populations, particularly in patients with TAVI and bioprosthetic valve, and to determine whether they could be used in the future in the two remaining contraindications.
Disclosures
No extramural funding was used to support this work. The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the paper and its final contents
Figure legend
Flow chart to guide decision making in patients with atrial fibrillation.
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13 Tables   Trial  Molecule  Exclusion criteria RE-LY Dabigatran History of heart valve disorder (i.e., prosthetic valve or hemodynamically relevant valve disease)
ROCKET-AF Rivaroxaban
Hemodynamically significant mitral valve stenosis, prosthetic heart valves (annuloplasty with or without prosthetic ring, commisurotomy and/or valvuloplasty are permitted)
ARISTOTLE
Apixaban
Conditions other than AF that require anticoagulation (i.e.
prosthetic heart valves)
ENGAGE AF Edoxaban
Moderate-to-severe mitral stenosis, other indication for anticoagulation (subjects with bioprosthetic heart valves and/or valve repair could be included) 
